Strides Pharma Science obtains USFDA approval for Ursodiol capsules
Category: #headlines |   By Pankaj Singh |   Date: 2021-01-27

Strides Pharma Science obtains USFDA approval for Ursodiol capsules

Strides Pharma Science Ltd., a leading manufacturer of soft gelatin capsules, has reportedly received a green light from the health regulator USFDA (United States Food and Drug Administration) for commercializing generic Ursodiol capsules which will be used in treating PBC (Primary Biliary Cirrhosis) in America.

Credible sources cited that the company's wholly-owned division, Strides Pharma Global Pte Ltd., Singapore, has received approval from the US FDA for marketing Ursodiol capsules in 300mg. The company said that its product is bioequivalent and therapeutically equivalent to the Actigall capsules developed by Allergan.

Strides Pharma Global added that the product will be developed at the pharma firm’s Bengaluru facility and will be commercialized by Strides Pharma Inc. in the United States.

It is worth noting that Ursodiol capsules USP 400 Mg is worth USD 45 million in the U.S. market, as claimed in the November 2020 data published by IQVIA. In the previous week, the drug firm was granted permission from the U.S. regulator for the use of Emtricitabine and Tenofovir Disoproxil Fumarate tablets for treating patients suffering from HIV, cited sources knowledgeable with the matter.

According to reliable sources, Strides Pharma has a total of 127 new drug application filings with USFDA of which 96 have already been approved, whereas 31 are pending approval. The company’s stock has increased significantly by 12% over the last three months, however, inconsistent financials remain a concern, cite reliable sources.

About Strides Pharma Science Limited

Founded in 1990 by Arun Kuma, Strides Shasun Limited, later renamed Strides Pharma Science Limited, is a pharmaceutical organization based in Bangalore, India. Strides Pharma is primarily involved in the development of IP-based niche finished dosage formulations and mainly operates in regulated markets of Australia, the U.S., Europe, and Canada. It boasts of a team of 2500 people across seven global manufacturing sites, five of which are USFDA approved facilities.

Source Credits –

https://www.moneycontrol.com/news/trends/health-trends/strides-pharma-gets-usfda-nod-for-generic-drug-6393071.html

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh     Twitter

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with Read more...

More News By Pankaj Singh

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

By Pankaj Singh

Airwaive and Shaurrya Teleservices (STS) has reportedly announced an international strategic collaboration to jointly build 5G wireless network service in India, assisting telecom providers in advancing 5G technology throughout the nation. Notably...

Valneva looking to capitalize on growing prevalence of Lyme disease

Valneva looking to capitalize on growing prevalence of Lyme disease

By Pankaj Singh

French drugmaker Valneva SE is now reportedly betting on its vaccine VLA15 for treating climate change-induced Lyme disease, as it looks to capitalize on growing prevalence of tick-borne illnesses following the disappointing sales of its COVID-19 vac...

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

By Pankaj Singh

Reliance Jio Infocomm Ltd., owned by billionaire industrialist Mukesh Ambani, was found to be the most aggressive participant in the government-backed 5G auction in India where several telecom behemoths agreed to invest at least USD 19 billion. Jio w...